{"disease":{"id":"gynecologic-malignancy","name":"gynecologic malignancy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06654440","title":"A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Shanghai Hengrui Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06997887","title":"Promotion of Vaginal Health With CH2 Vaginal Gel After Pelvic Radiotherapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}